This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Seliciclib
Accession Number
DB06195
Type
Small Molecule
Groups
Investigational
Description

R-roscovitine (Seliciclib or CYC202) is a trial drug in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel. Seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.

Structure
Thumb
Synonyms
  • CYC202
  • R-roscovitine
External IDs
AL-39256 / CYC-202 / NSC-701554
Categories
UNII
0ES1C2KQ94
CAS number
186692-46-6
Weight
Average: 354.4493
Monoisotopic: 354.216809484
Chemical Formula
C19H26N6O
InChI Key
BTIHMVBBUGXLCJ-OAHLLOKOSA-N
InChI
InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
IUPAC Name
(2R)-2-{[6-(benzylamino)-9-(propan-2-yl)-9H-purin-2-yl]amino}butan-1-ol
SMILES
CC[C@H](CO)NC1=NC(NCC2=CC=CC=C2)=C2N=CN(C(C)C)C2=N1

Pharmacology

Indication

Investigated for use/treatment in breast cancer, lung cancer, lymphoma (unspecified), multiple myeloma, leukemia (lymphoid), and cancer/tumors (unspecified).

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCyclin-dependent kinase 1Not AvailableHuman
UCyclin-dependent kinase 2Not AvailableHuman
UMitogen-activated protein kinase 3Not AvailableHuman
UMitogen-activated protein kinase 1Not AvailableHuman
UCyclin-dependent kinase 7Not AvailableHuman
UCyclin-dependent kinase 9Not AvailableHuman
UCasein kinase I isoform epsilonNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Seliciclib.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Seliciclib.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Seliciclib.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Seliciclib.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Seliciclib.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Seliciclib.Approved, Experimental, Investigational
AcenocoumarolSeliciclib may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Seliciclib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Seliciclib.Experimental
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Seliciclib.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Seliciclib.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Seliciclib.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Seliciclib.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Seliciclib.Experimental, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Seliciclib.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Seliciclib.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Seliciclib.Approved, Investigational, Withdrawn
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Seliciclib.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Seliciclib.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Seliciclib.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Seliciclib.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Seliciclib.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Seliciclib.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Seliciclib.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Seliciclib.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Seliciclib.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Seliciclib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Seliciclib.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Seliciclib.Approved, Investigational
BazedoxifeneSeliciclib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Seliciclib.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Seliciclib.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Seliciclib.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Seliciclib.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Seliciclib.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Seliciclib.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Seliciclib.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Seliciclib.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Seliciclib.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Seliciclib.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Seliciclib.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seliciclib.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Seliciclib.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Seliciclib.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Seliciclib.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Seliciclib.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Seliciclib.Approved, Investigational, Vet Approved
ChlorotrianiseneSeliciclib may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Seliciclib.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Seliciclib.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Seliciclib.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Seliciclib.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Seliciclib.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Seliciclib.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Seliciclib.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Seliciclib.Approved
ClorindioneSeliciclib may increase the anticoagulant activities of Clorindione.Experimental
Conjugated estrogensSeliciclib may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Seliciclib.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Seliciclib.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Seliciclib.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Seliciclib.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Seliciclib.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Seliciclib.Experimental
DaidzeinSeliciclib may increase the thrombogenic activities of Daidzein.Experimental
DapoxetineDapoxetine may increase the antiplatelet activities of Seliciclib.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Seliciclib.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Seliciclib.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Seliciclib.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Seliciclib.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Seliciclib.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Seliciclib.Experimental, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Seliciclib.Vet Approved
DicoumarolSeliciclib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolSeliciclib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolSeliciclib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Seliciclib.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Seliciclib.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Seliciclib.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Seliciclib.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Seliciclib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Seliciclib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Seliciclib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Seliciclib.Approved
DiphenadioneSeliciclib may increase the anticoagulant activities of Diphenadione.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seliciclib.Approved, Investigational
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Seliciclib.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Seliciclib.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Seliciclib.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Seliciclib.Investigational
EpimestrolSeliciclib may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Seliciclib.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Seliciclib.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Seliciclib.Approved
EquolSeliciclib may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Seliciclib.Approved, Investigational
Estradiol acetateSeliciclib may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateSeliciclib may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateSeliciclib may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolSeliciclib may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedSeliciclib may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneSeliciclib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Seliciclib.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Seliciclib.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Seliciclib.Experimental
Ethyl biscoumacetateSeliciclib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Seliciclib.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Seliciclib.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Seliciclib.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Seliciclib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Seliciclib.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Seliciclib.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Seliciclib.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Seliciclib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Seliciclib.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Seliciclib.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Seliciclib.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Seliciclib.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Seliciclib.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Seliciclib.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Seliciclib.Approved, Investigational
FluindioneSeliciclib may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Seliciclib.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Seliciclib.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Seliciclib.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Seliciclib.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Seliciclib.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Seliciclib.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Seliciclib.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Seliciclib.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Seliciclib.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Seliciclib.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Seliciclib.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Seliciclib.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Seliciclib.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Seliciclib.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Seliciclib.Approved, Investigational, Withdrawn
GenisteinSeliciclib may increase the thrombogenic activities of Genistein.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Seliciclib.Experimental
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Seliciclib.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Seliciclib.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Seliciclib.Investigational
HexestrolSeliciclib may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Seliciclib.Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Seliciclib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Seliciclib.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Seliciclib.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Seliciclib.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Seliciclib.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Seliciclib.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Seliciclib.Withdrawn
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Seliciclib.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Seliciclib.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Seliciclib.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Seliciclib.Approved, Vet Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Seliciclib.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Seliciclib.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Seliciclib.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Seliciclib.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Seliciclib.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Seliciclib.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Seliciclib.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Seliciclib.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Seliciclib.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Seliciclib.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Seliciclib.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Seliciclib.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Seliciclib.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Seliciclib.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Seliciclib.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Seliciclib.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Seliciclib.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Seliciclib.Approved
MestranolSeliciclib may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Seliciclib.Approved, Investigational, Withdrawn
MethallenestrilSeliciclib may increase the thrombogenic activities of Methallenestril.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Seliciclib.Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Seliciclib.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Seliciclib.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Seliciclib.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Seliciclib.Approved, Vet Approved
MoxestrolSeliciclib may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Seliciclib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Seliciclib.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Seliciclib.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Seliciclib.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Seliciclib.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Seliciclib.Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Seliciclib.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Seliciclib.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Seliciclib.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Seliciclib.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Seliciclib.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Seliciclib.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Seliciclib.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Seliciclib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Seliciclib.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Seliciclib.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Seliciclib.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Seliciclib.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Seliciclib.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seliciclib.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Seliciclib.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Seliciclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Seliciclib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Seliciclib.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Seliciclib.Experimental
PhenindioneSeliciclib may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonSeliciclib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Seliciclib.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seliciclib.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Seliciclib.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Seliciclib.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Seliciclib.Experimental
Polyestradiol phosphateSeliciclib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Seliciclib.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Seliciclib.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Seliciclib.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Seliciclib.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Seliciclib.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Seliciclib.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Seliciclib.Experimental
PromestrieneSeliciclib may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Seliciclib.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Seliciclib.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Seliciclib.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Seliciclib.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Seliciclib.Investigational
QuinestrolSeliciclib may increase the thrombogenic activities of Quinestrol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Seliciclib.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Seliciclib.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Seliciclib.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Seliciclib.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Seliciclib.Approved
SecoisolariciresinolSeliciclib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Seliciclib.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Seliciclib.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Seliciclib.Investigational
SertralineSertraline may increase the antiplatelet activities of Seliciclib.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Seliciclib.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Seliciclib.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Seliciclib.Experimental
Synthetic Conjugated Estrogens, ASeliciclib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BSeliciclib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Seliciclib.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Seliciclib.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Seliciclib.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Seliciclib.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Seliciclib.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Seliciclib.Approved
TiboloneSeliciclib may increase the thrombogenic activities of Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Seliciclib.Investigational
TioclomarolSeliciclib may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Seliciclib.Approved, Withdrawn
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Seliciclib.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Seliciclib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Seliciclib.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Seliciclib.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Seliciclib.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Seliciclib.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Seliciclib.Approved, Investigational, Withdrawn
WarfarinSeliciclib may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Seliciclib.Approved, Investigational
ZeranolSeliciclib may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Seliciclib.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Seliciclib.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Seliciclib.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
160355
ChemSpider
140922
BindingDB
7533
ChEBI
45307
ChEMBL
CHEMBL14762
HET
RRC
Wikipedia
Seliciclib
PDB Entries
1unl / 1ygk / 2a4l / 3ddq

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentAdvanced Solid Tumors1
1WithdrawnTreatmentCancer, Breast1
2CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
2RecruitingTreatmentCushings Disease1
2TerminatedTreatmentCystic Fibrosis (CF)1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.163 mg/mLALOGPS
logP3.11ALOGPS
logP2.89ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)14.34ChemAxon
pKa (Strongest Basic)5.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area87.89 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity106.14 m3·mol-1ChemAxon
Polarizability40.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.5569
Caco-2 permeable-0.5933
P-glycoprotein substrateSubstrate0.8191
P-glycoprotein inhibitor INon-inhibitor0.7527
P-glycoprotein inhibitor IINon-inhibitor0.8302
Renal organic cation transporterNon-inhibitor0.7794
CYP450 2C9 substrateNon-substrate0.8193
CYP450 2D6 substrateNon-substrate0.788
CYP450 3A4 substrateNon-substrate0.5703
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.5687
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8394
Ames testNon AMES toxic0.6143
CarcinogenicityNon-carcinogens0.8402
BiodegradationNot ready biodegradable0.9862
Rat acute toxicity2.6040 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Non-inhibitor0.55
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 6-alkylaminopurines. These are compounds that contain an alkylamine group attached at the 6-position of a purine. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
6-alkylaminopurines
Alternative Parents
Benzylamines / Secondary alkylarylamines / Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Heteroaromatic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
6-alkylaminopurine / Benzylamine / Aminopyrimidine / Secondary aliphatic/aromatic amine / Monocyclic benzene moiety / N-substituted imidazole / Pyrimidine / Benzenoid / Imidolactam / Imidazole
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
2,6-diaminopurine (CHEBI:45307)

Targets

Details
1. Cyclin-dependent kinase 1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Rna polymerase ii carboxy-terminal domain kinase activity
Specific Function
Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition, and regulates G1 progress and G1-S transition via...
Gene Name
CDK1
Uniprot ID
P06493
Uniprot Name
Cyclin-dependent kinase 1
Molecular Weight
34095.14 Da
References
  1. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Levi F: Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2006 Nov 15;66(22):10720-8. [PubMed:17108108]
Details
2. Cyclin-dependent kinase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N...
Gene Name
CDK2
Uniprot ID
P24941
Uniprot Name
Cyclin-dependent kinase 2
Molecular Weight
33929.215 Da
References
  1. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Levi F: Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2006 Nov 15;66(22):10720-8. [PubMed:17108108]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphatase binding
Specific Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK ca...
Gene Name
MAPK3
Uniprot ID
P27361
Uniprot Name
Mitogen-activated protein kinase 3
Molecular Weight
43135.16 Da
References
  1. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Levi F: Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2006 Nov 15;66(22):10720-8. [PubMed:17108108]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Rna polymerase ii carboxy-terminal domain kinase activity
Specific Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK ca...
Gene Name
MAPK1
Uniprot ID
P28482
Uniprot Name
Mitogen-activated protein kinase 1
Molecular Weight
41389.265 Da
References
  1. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Levi F: Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2006 Nov 15;66(22):10720-8. [PubMed:17108108]
Details
5. Cyclin-dependent kinase 7
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcription coactivator activity
Specific Function
Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the ...
Gene Name
CDK7
Uniprot ID
P50613
Uniprot Name
Cyclin-dependent kinase 7
Molecular Weight
39038.005 Da
References
  1. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Levi F: Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2006 Nov 15;66(22):10720-8. [PubMed:17108108]
Details
6. Cyclin-dependent kinase 9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcription regulatory region dna binding
Specific Function
Protein kinase involved in the regulation of transcription. Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), whic...
Gene Name
CDK9
Uniprot ID
P50750
Uniprot Name
Cyclin-dependent kinase 9
Molecular Weight
42777.155 Da
References
  1. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Levi F: Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2006 Nov 15;66(22):10720-8. [PubMed:17108108]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine kinase activity
Specific Function
Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Can phosphorylate a large number of proteins. Participates in Wnt signal...
Gene Name
CSNK1E
Uniprot ID
P49674
Uniprot Name
Casein kinase I isoform epsilon
Molecular Weight
47314.665 Da
References
  1. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Levi F: Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2006 Nov 15;66(22):10720-8. [PubMed:17108108]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP: R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 2008 Feb;15(2):263-73. Epub 2007 Nov 2. [PubMed:17975552]

Drug created on March 19, 2008 10:16 / Updated on August 02, 2018 05:34